News | January 30, 2012

ACC 2012 Late Breaking Trial Presentations Announced

January 30, 2012 - The 2012 American College of Cardiology (ACC) meeting in Chicago, March 24-26, includes five sessions of late-breaking trials. The ACC announced the following trials will be included:

Opening Session and Late-Breaking Clinical Trials
Session 300
Saturday, March 24, 2012, 8–10 a.m.
McCormick Place North, Hall B, ACC.12 Main Tent

  • Effect of Transendocardial Autologous Bone Marrow Mononuclear Cell Delivery on Functional Capacity, Left Ventricular Function and Perfusion in Chronic Ischemic Heart Failure: The FOCUS Randomized Trial
    Emerson C. Perin, James Willerson, Stephen Ellis, Timothy Henry, Carl Pepine, David Zhao, Dejian Lai, Barry Byrne, Antonis Hatzopoulos, Marc Penn, Jay Traverse, Adrian Gee, Marvin Kronenberg, Daniel Martin, James Thomas, Doris Taylor, Christopher Cogle, Sonia Skarlatos, Lem Moye, Robert Simari, Cardiovascular Cell Therapy Research Network (CCTRN), Houston, Texas
  • Evaluation of a Novel Antiplatelet Agent for Secondary Prevention in Patients with Atherosclerotic Disease: Results of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P): TIMI 50 Trial
    David A. Morrow, Brigham & Women's Hospital, Boston

Late-Breaking Clinical Trials II
Session 304
Sunday, March 25, 2012, 8–9:30 a.m.
McCormick Place North, Hall B, ACC.12 Main Tent

  • Outcomes of Non-Primary PCI at Hospitals with and without On-site Cardiac Surgery: CPORT-E Trial. Final Medical Outcomes
    Thomas Aversano, Johns Hopkins University, Baltimore
  • INFUSE-AMI: A 2x2 Factorial, Multicenter, Prospective, Randomized Evaluation of Intracoronary Abciximab and Aspiration Thrombectomy in Patients Undergoing Primary PCI for Anterior STEMI
    Gregg W. Stone, Akiko Maehara, Bernhard Witzenbichler, Jan Godlewski, Ecaterina Cristea, Helen Parise, Jan Henk Dembrink, Andrzej Ochala, Steven Wolff, Saqib Chowdhary, Magdi El-Omar, Thomas D Neunteuff, D. Christopher Metzger, C. Michael Gibson, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, N.Y.
  • Randomized Comparison of Adding Cilostazol Versus Doubling the Dose of Clopidogrel after Receiving Percutaneous Coronary Intervention: The HOST-ASSURE Randomized Trial
    Kyung Woo Park, Hyo Soo Kim, Hyun-Jae Kang, Bon-Kwon Koo, In-Ho Chae, Seoul National University Hospital, Seoul, South Korea
  • A Multifaceted Intervention to Narrow the Evidence-Based Gap in the Treatment of Acute Coronary Syndromes: Main Results from the BRIDGE-ACS Cluster Randomized Trial
    Otavio Berwanger, Helio Guimaraes, Alexandre Cavalcanti, Ligia Laranjeira, Eliana Santucci, Ana Zazula, Uri Flato, Marcos Tenuta, Alessandra Kodama, Elivane Victor, Mariana Carballo, Vera Mira, Luiz Mota, Eric Peterson, Renato Lopes, Research Institute of Cardiac Hospital (HCor), Sao Paulo, Brazil, Brazilian Clinical Research  Institute, Sao Paulo, Brazil


Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Session 305
Monday, March 26, 2012, 8–9:30 a.m.
McCormick Place North, Hall B, ACC.12 Main Tent

  • CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study
    Andre Lamy, on behalf of the CORONARY Study Investigators, Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada
  • ACRIN PA 4005: Multicenter Randomized Controlled Study of a Rapid “Rule Out” Strategy Using CT Coronary Angiogram Versus Traditional Care for Low-Risk ED Patients with Potential Acute Coronary Syndromes
    Harold Litt, Chadwick Miller, Constantine Gatsonis, Brad Snyder, Harjit Singh, Laurence Gavin, Daniel Entrikin, James Leaming, Carlos Jamis-Dow, Joan Lacomis, Judd Hollander, University of Pennsylvania, Philadelphia, American College of Radiology Imaging Network, Philadelphia
  • Oral Rivaroxaban Alone for Symptomatic Pulmonary Embolism: The EINSTEIN PE Study
    Harry Roger Buller, Academic Medical Center, Amsterdam, The Netherlands
  • Late (? 2 year) Clinical and Echocardiographic Outcomes after Transcatheter vs. Surgical Aortic Valve Replacement: Results from the High-Risk Cohort of the PARTNER Trial
    Martin Leon, John Webb, Jeffrey Moses, Michael Mack, D. Craig Miller, Lars Svensson, E. Murat Tuzcu, Craig Smith, for the PARTNER Trial Investigators, Columbia University Medical Center and The Cardiovascular Research Foundation, New York, N.Y.

Late-Breaking Clinical Trials IV
Session 306
Monday, March 26, 2012 10:30 a.m. – Noon
McCormick Place North, Hall B, ACC.12 Main Tent

  • Comparison of Bariatric Surgical Procedures and Advanced Medical Therapy for the Treatment of Type 2 Diabetes in Patients with Moderate Obesity: 1-year STAMPEDE Trial Results
    Philip Raymond Schauer, Sangeeta Kashyap, Kathy Wolski, Stacy Brethauer, John Kirwanj, Claire Pothier, Susan Thomas, Beth Abood, Steven Nissen, Deepak Bhatt, Cleveland Clinic, Cleveland, Ohio
  • A Mendelian Randomized Controlled Trial of Long Term Reduction in Low-Density Lipoprotein Cholesterol Beginning Early in Life
    Brian Anthony Ference, Nitin Mahajan, Issa Alesh, Wonsuk Yoo, Karolina K. Mirowska, Abhishek Mewada, Luis Afonso, Joel Kahn, Kim Williams, John Flack, Wayne State University School of Medicine, Detroit
  • A Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, REGN727/SAR236553, in Patients with Primary Hypercholesterolemia (NCT: 01288443)
    James McKenney, Michael Koren, Dean Kereiakes, Corinne Hanotin, ANNE-CATHERINE FERRAND, Evan Albert Stein, Regeneron Pharmaceuticals, Incorporated, Tarrytown, N.Y., Sanofi-aventis U.S. Inc., Bridgewater, N.J.
  • Pacemaker Therapy in Patients with Neurally-mediated Syncope and Documented Asystole
    Michele Brignole, on the behalf of the ISSUE-3 investigators, Ospedali del Tigullio, Lavagna, Italy


Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Session 308
Tuesday, March 27, 2012 8–9:30 a.m.
McCormick Place North, Hall B, ACC.12 Main Tent

  • Survival after PCI or CABG in Older Patients with Stable Multivessel Coronary Disease: Results from the ACCF-STS Database Collaboration on the Comparative Effectiveness of Revascularization Strategies
    William S. Weintraub, Maria V. Grau-Sepulveda, Jocelyn Weiss, Sean O'Brien, Eric Peterson, Paul Kolm, Zugui Zhang, Lloyd Klein, Richard Shaw, Charles McKay, Laura Ritzenthaler, Jeffrey Popma, John Messenger, David Shahian, Frederick Grover, John Mayer, Cynthia M. Shewan, Kirk Garratt, Issam Moussa, George Dangas, Fred Edwards, American College of Cardiology, Washington, D.C., The Society of Thoracic Surgeons, Chicago

  • Multicenter Randomized Comparative Effectiveness Trial of Cardiac CT vs Alternative Triage Strategies in Acute Chest Pain Patients in the Emergency Department: Results from the ROMICAT II Trial
    Udo Hoffmann, Quynh Truong, Hang Lee, Eric Chou, Pamela Woodard, john nagurney, James H. Pope, Thomas Hauser, Charles White, Scott Weiner, Alexander Goehler, Pearl Zakroysky, Ruth Kirby, Douglas Hayden, Stephen Wiviott, Jerome Fleg, Scott Gazelle, David Schoenfeld, James Udelson, Massachusetts General Hospital - Cardiac MR PET CT Program, Boston
  • Results of the IMMEDIATE (Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care) Trial: A Double-Blind Randomized Controlled Trial of Intravenous Glucose, Insulin, and Potassium (GIK) for Acute Coronary Syndromes in Emergency Medical Services
    Harry P. Selker, Joni R. Beshansky, Patricia R. Sheehan, Robin Ruthazer, John L. Griffith, James E. Udelson, Joseph M. Massaro, Ralph B. D'Agostino, IMMEDIATE Trial Investigators, Tufts Medical Center, Boston
  • Moderate Pulmonary Embolism Treated with Thrombolysis (MOPETT Study)
    Mohsen Sharifi, Curt Bay, Laura Skrocki, Farnoosh Rahimi, Mahshid Mehdipour, Arizona Cardiovascular Consultants, Mesa, Ariz., A.T.Still University, Mesa, Ariz.


For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init